These findings highlight the potential clinical utility of CDX2 as a prognostic (providing information about likelihood of disease progression or outcome regardless of treatment) and predictive (providing information about likelihood of response to a particular therapy) biomarker in CRC and emphasises the importance of incorporating biomarker testing in routine practice [21]. This evidence concerns the gene CDX2 and colorectal carcinoma.